Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 4 3Phase 1 3Phase NA 2Phase EARLY_PHASE1 2Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Invasive Fungal Infections 1Hematologic Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × posaconazole × Clear all
NCT00750737 2016-09-29

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

M.D. Anderson Cancer Center

Phase 3 Completed
46 enrolled 6 charts
Other hematologic neoplasm

Invasive Fungal Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡